Maureen Edgerly

2.0k total citations
27 papers, 792 citations indexed

About

Maureen Edgerly is a scholar working on Oncology, Cancer Research and Surgery. According to data from OpenAlex, Maureen Edgerly has authored 27 papers receiving a total of 792 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 13 papers in Cancer Research and 12 papers in Surgery. Recurrent topics in Maureen Edgerly's work include Cancer Treatment and Pharmacology (10 papers), Adrenal and Paraganglionic Tumors (10 papers) and Cancer, Hypoxia, and Metabolism (9 papers). Maureen Edgerly is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Adrenal and Paraganglionic Tumors (10 papers) and Cancer, Hypoxia, and Metabolism (9 papers). Maureen Edgerly collaborates with scholars based in United States, Chile and Denmark. Maureen Edgerly's co-authors include Tito Fojo, Susan E. Bates, Frank M. Balis, Manish Agrawal, Jame Abraham, Herb Kotz, Ann Rutt, Susan Bakke, Wilfred D. Stein and Christine Grady and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and JNCI Journal of the National Cancer Institute.

In The Last Decade

Maureen Edgerly

27 papers receiving 770 citations

Peers

Maureen Edgerly

ONCOL

SURGE

GENET

Thomas J. Semrad United States

J. Wendall Goodwin United States

Els O. Witteveen Netherlands

Martha Donoghue United States

Nancy B. Davis United States

Dipesh Uprety United States

Paul A. S. Fishkin United States

Matthew Burge Australia

Encarna Adrover Spain

Meredith K. Chuk United States

Thomas J. Semrad United States

Maureen Edgerly

395 ×0.9

ONCOL

162 ×0.7

122 ×0.6

SURGE

257 ×1.6

67 ×0.6

GENET

Citations per year, relative to Maureen Edgerly Maureen Edgerly (= 1×) peers Thomas J. Semrad

Countries citing papers authored by Maureen Edgerly

Since Specialization

Citations

This map shows the geographic impact of Maureen Edgerly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maureen Edgerly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maureen Edgerly more than expected).

Fields of papers citing papers by Maureen Edgerly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maureen Edgerly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maureen Edgerly. The network helps show where Maureen Edgerly may publish in the future.

Co-authorship network of co-authors of Maureen Edgerly

This figure shows the co-authorship network connecting the top 25 collaborators of Maureen Edgerly. A scholar is included among the top collaborators of Maureen Edgerly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maureen Edgerly. Maureen Edgerly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fojo, Tito, Andrea B. Apolo, Maureen Edgerly, et al.. (2024). Single agent axitinib in the management of patients with progressive pheochromocytoma and paraganglioma.. Journal of Clinical Oncology. 42(16_suppl). 4602–4602. 2 indexed citations

Venzon, David, David J. Liewehr, Maureen Edgerly, et al.. (2021). Tumor Doubling Time Using CT Volumetric Segmentation in Metastatic Adrenocortical Carcinoma. Current Oncology. 28(6). 4357–4366. 2 indexed citations

Mauda‐Havakuk, Michal, Elizabeth Levin, Elliot Levy, et al.. (2021). Long‐term outcomes in patients with advanced adrenocortical carcinoma after image‐guided locoregional ablation or embolization. Cancer Medicine. 10(7). 2259–2267. 7 indexed citations

Fojo, Tito, Lyn M. Huff, Thomas Litman, et al.. (2020). Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape. BMC Medical Genomics. 13(1). 165–165. 19 indexed citations

Edgerly, Maureen, et al.. (2018). Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer. The Oncologist. 24(1). 16–e14. 16 indexed citations

Burotto, Mauricio, Maureen Edgerly, Marianne S. Poruchynsky, et al.. (2015). Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma. The Oncologist. 20(7). 725–726. 8 indexed citations

Burotto, Mauricio, Nishant Tageja, Avi Z. Rosenberg, et al.. (2014). Brain Metastasis in Patients With Adrenocortical Carcinoma: A Clinical Series. The Journal of Clinical Endocrinology & Metabolism. 100(2). 331–336. 12 indexed citations

O’Sullivan, Ciara C., Maureen Edgerly, Julia Wilkerson, et al.. (2014). The VEGF Inhibitor Axitinib Has Limited Effectiveness as a Therapy for Adrenocortical Cancer. The Journal of Clinical Endocrinology & Metabolism. 99(4). 1291–1297. 80 indexed citations

Ho, Jennifer, Barış Türkbey, Maureen Edgerly, et al.. (2013). Role of Radiotherapy in Adrenocortical Carcinoma. The Cancer Journal. 19(4). 288–294. 29 indexed citations

10.

Huang, Hui, Michael E. Menefee, Maureen Edgerly, et al.. (2010). A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research. 16(5). 1634–1641. 34 indexed citations

11.

Abraham, Jame, Maureen Edgerly, Richard H. Wilson, et al.. (2009). A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine. Clinical Cancer Research. 15(10). 3574–3582. 93 indexed citations

12.

Stein, Wilfred D., Hui Huang, Michael E. Menefee, et al.. (2009). Other Paradigms: Growth Rate Constants and Tumor Burden Determined Using Computed Tomography Data Correlate Strongly With the Overall Survival of Patients With Renal Cell Carcinoma. The Cancer Journal. 15(5). 441–447. 31 indexed citations

13.

Grady, Christine & Maureen Edgerly. (2009). Science, Technology, and Innovation: Nursing Responsibilities in Clinical Research. Nursing Clinics of North America. 44(4). 471–481. 32 indexed citations

14.

Menefee, Michael E., Hongyun Huang, Maureen Edgerly, et al.. (2008). Effects of the P-glycoprotein (Pgp) antagonist tariquidar (XR-9576; TQD) on Pgp function as well as the toxicity and efficacy of combined chemotherapy in patients with metastatic adrenocortical cancer (mACC). Journal of Clinical Oncology. 26(15_suppl). 2543–2543. 3 indexed citations

15.

Edgerly, Maureen & Tito Fojo. (2008). Is There Room for Improvement in Adverse Event Reporting in the Era of Targeted Therapies?. JNCI Journal of the National Cancer Institute. 100(4). 240–242. 46 indexed citations

16.

Zhuang, Sen Hong, Manish Agrawal, Maureen Edgerly, et al.. (2005). A Phase I clinical trial of ixabepilone (BMS‐247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer. 103(9). 1932–1938. 61 indexed citations

17.

Fojo, Antonio Tito, Michael E. Menefee, Marianne S. Poruchynsky, et al.. (2005). A translational study of ixabepilone (BMS-247550) in renal cell cancer (RCC): Assessment of its activity and demonstration of target engagement in tumor cells. Journal of Clinical Oncology. 23(16_suppl). 4541–4541. 23 indexed citations

18.

Agrawal, Manish, Maureen Edgerly, Tito Fojo, & Herb Kotz. (2003). Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analog. Gynecologic Oncology. 90(1). 96–99. 9 indexed citations

19.

Abraham, Jame, Manish Agrawal, Susan Bakke, et al.. (2003). Phase I Trial and Pharmacokinetic Study of BMS-247550, an Epothilone B Analog, Administered Intravenously on a Daily Schedule for Five Days. Journal of Clinical Oncology. 21(9). 1866–1873. 113 indexed citations

20.

Sei, Shizuko, et al.. (2001). Protective effect of CCR5 Δ32 heterozygosity is restricted by SDF-1 genotype in children with HIV-1 infection. AIDS. 15(11). 1343–1352. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact